Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study

Table 2 Cox’s proportional hazards analysis for the combined endpoint of hepatocellular carcinoma occurrence or death from any cause

	Univariate analysis		Multivariate analysis
Variable	HR (95%CI)	P value	HR (95%CI)	P value
Age (yr)	1.003 (0.968-1.040)	0.862	1.008 (0.958-1.060)	0.760
Male (no/yes)	1.334 (0.538-3.308)	0.534	2.492 (0.683-9.089)	0.167
HCV viremia (log n)	0.811 (0.698-0.944)	0.007	0.808 (0.666-0.980)	0.030
Cirrhosis (no/yes)	9.259 (2.705-31.70)	< 0.001	3.392 (0.861-13.37)	0.081
Platelet count (n × 104/mL)	0.806 (0.735-0.885)	< 0.001	0.910 (0.831-0.996)	0.041
eGFR (10 mL/min/1.73 m2)	0.935 (0.780-1.122)	0.473	0.774 (0.596-1.005)	0.055
Mixed cryoglobulinemia (no/yes)	4.522 (1.822-11.23)	0.001	3.460 (1.035-11.56)	0.044
SVR (no/yes)	0.035 (0.015-0.084)	< 0.001	0.070 (0.025-0.194)	< 0.001

HCV: Hepatocellular C virus; SVR: Sustained virologic response; HR: Hazard ratio; CI: Confidence interval; eGFR: Estimated glomerular filtration rate.